| Literature DB >> 29227283 |
Hironari Tamiya1, Hyungsoo Kim1, Oleksiy Klymenko2, Heejung Kim1, Yongmei Feng1, Tongwu Zhang3, Ji Yun Han1, Ayako Murao1, Scott J Snipas1, Lucia Jilaveanu4, Kevin Brown3, Harriet Kluger4, Hao Zhang5, Kazuhiro Iwai6, Ze'ev A Ronai1,2.
Abstract
SHARPIN, an adaptor for the linear ubiquitin chain assembly complex (LUBAC), plays important roles in NF-κB signaling and inflammation. Here, we have demonstrated a LUBAC-independent role for SHARPIN in regulating melanoma growth. We observed that SHARPIN interacted with PRMT5, a type II protein arginine methyltransferase, and increased its multiprotein complex and methyltransferase activity. Activated PRMT5 controlled the expression of the transcription factors SOX10 and MITF by SHARPIN-dependent arginine dimethylation and inhibition of the transcriptional corepressor SKI. Activation of PRMT5 by SHARPIN counteracted PRMT5 inhibition by methylthioadenosine, a substrate of methylthioadenosine phosphorylase, which is codeleted with cyclin-dependent kinase inhibitor 2A (CDKN2A) in approximately 15% of human cancers. Collectively, we identified a LUBAC-independent role for SHARPIN in enhancing PRMT5 activity that contributes to melanomagenesis through the SKI/SOX10 regulatory axis.Entities:
Keywords: Cancer; Cell Biology; Melanoma; Oncology; Signal transduction
Mesh:
Substances:
Year: 2017 PMID: 29227283 PMCID: PMC5749505 DOI: 10.1172/JCI95410
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808